Pacira BioSciences Inc (PCRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Pacira BioSciences Inc (Pacira), formerly Pacira Pharmaceuticals Inc, provides non-opioid pain management and regenerative health solutions. The company develops drugs based on its proprietary DepoFoam drug delivery technology. Its lead product candidate, Exparel (bupivacaine liposome injectable suspension) is an amide-type local anesthetic administered at the time of surgery to control pain and eliminate the use of opioids for acute postsurgical pain. Its other products include iovera, a non-opioid treatment intended to block pain, and relieve pain and symptoms related to osteoarthritis of the knee; among others. Its products are essentially used by hospitals, doctors and ambulatory surgery centers. It also sells products through co-promotion agreements and supply agreements with other pharmaceutical companies. The company has operations in the US and the UK. Pacira is headquartered in Tampa, Florida, the US.Pacira BioSciences Inc Key Recent Developments
- Mar 22, 2023: Pacira BioSciences Announces Yvonne Greenstreet to Retire from Board of Directors
- Feb 28, 2023: Pacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results
- Jan 05, 2023: Pacira BioSciences Reports Preliminary Unaudited Total Revenue for 2022 of $666.8 Million
- Nov 17, 2022: New research reveals common treatments for knee pain are falling short, placing physical, social, and mental burden on patients
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Section 1 - About the Company
Section 2 - Company Analysis
Section 3 - Company Financial Ratios
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Section 5 - Company’s Recent Developments
Section 6 - Appendix
List of Tables
List of Figures
Samples
LOADING...
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- DURECT Corp
- AcelRx Pharmaceuticals Inc
- Roche Holding, Ltd.
- AcelRx Pharmaceuticals Inc
- Scilex Pharmaceuticals Inc
- Napp Pharmaceuticals Ltd
- Akorn Operating Company LLC
- DURECT Corp
- Akorn Inc
- Scilex Pharmaceuticals Inc
- Napp Pharmaceuticals Ltd
- Roche Holding, Ltd.